This drug extends survival for patients with aggressive breast cancer
What's the story
AstraZeneca's latest drug, Datroway, has shown promising results in extending survival for patients with advanced triple-negative breast cancer (TNBC). The findings from a major 2024 study reveal that this is the first real survival boost for these patients. The study was presented at the European Society for Medical Oncology Congress today.
Survival advantage
Datroway outperformed standard chemotherapy
In the TROPION-Breast02 trial, patients taking Datroway had a median overall survival of 23.7 months, compared to just 18.7 months for those on standard chemotherapy. The new drug also delayed disease progression, suggesting it could change the way TNBC is treated in the future. "This is the first time we show survival superiority of a new approach like Datroway versus standard chemotherapy," said Abder Laadem, head of late-stage clinical development oncology at Daiichi Sankyo.
Innovative technology
Drug delivered directly into tumor cells
Datroway uses Daiichi Sankyo's DXd technology to deliver a cytotoxic payload directly into tumor cells while minimizing toxicity. Patients were on the drug for twice as long as chemotherapy, but without an increase in severe side effects or new safety concerns. "The drug's design ensures targeted delivery and reduces toxicity," said Susan Galbraith, AstraZeneca's Executive Vice President of Oncology R&D.
Treatment revolution
Two ADCs could treat nearly all breast cancer patients
Datroway now joins Enhertu, another DXd-based drug, in the modern treatment of breast cancer. AstraZeneca and Daiichi Sankyo's joint effort has produced two ADCs that could potentially treat 90% of women with breast cancer. "These drugs have the chance to become the standard of care for 90% of women," said Ken Keller, global oncology head at Daiichi Sankyo.